ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1484

Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis

Catherine Sullivan1, Gadintshware Gaoatswe2, James Gibney3, Marie Louise Healy4, Michele Doran5, David Kane1, Donal O'Shea2 and Ronan Mullan1, 1Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, 2Obesity Immunology Group, Education and Research Centre, St Vincent's University Hospital, UCD, Dublin 4, Ireland, 3Department of Endocrinology, Tallaght Hospital, TCD, Dublin 24, Ireland, 4Department of Endocrinology, St James Hospital, TCD, Dublin 8, Ireland, 5Rheumatology Dept, St James's Hospital, Dublin, Ireland

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Diabetes, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Glucagon-like peptide-1 (GLP-1) analogues such as liraglutide, which are used for the treatment of type 2 diabetes (T2DM), mimic the action of endogenous incretin hormones through both enhancing post-prandial pancreatic glucose-dependent insulin release and promoting early satiety. Recent evidence indicates novel anti-inflammatory effects of GLP-1 analogues, including the amelioration of TNF inflammatory responses on human endothelial cells, and reduction in monocyte TLR2, TLR4 and TNF expression following treatment with GLP-1 analogues for T2DM. We have previously shown decreased inflammatory activity of invariant Natural Killer T (iNKT), modulation of monocyte cytokine secretion and amelioration of skin psoriasis in a cohort of patients with concomitant psoriasis and T2DM. Here we investigate a role for liraglutide in the amelioration of inflammatory arthritis disease activity in a cohort of patients undergoing liraglutide treatment for concomitant T2DM. 

Methods: Following institutional ethics committee approval, patients with T2DM and a concomitant diagnosis of either rheumatoid arthritis (n=11) or psoriatic arthritis (n=4 ) were recruited from rheumatology out patient clinics and commenced on the GLP-1 analogue, liraglutide 1.2mg s/c od. No changes were made to patient Disease Modifying Anti Rheumatic or biological drug therapies for the duration of the study. DAS28 scores, weight, HbA1C, were recorded at baseline and weeks 6, 12 and 24. DAS28 outcomes were  defined by EULAR good, or moderate vs non-responders. Results expressed as Mean + SE.

Results:  Patients had active arthritis (DAS28 4.38 + 0.4) and inadequate glycaemic control Hba1C (55 + 5.1) at baseline. Following liraglutide therapy 9 patients achieved DAS28 response (DAS28 = 4.2 + 0.8 pre, 2.7 + 0.5 post) vs 6 non-responders (DAS28 = 4.7 + 0.8 pre, 5.0 + 2.7 post ). Significant weight loss was seen in DAS28 responders (94 + 5 pre, 90.6 + 5.2kg, p=0.008) but not non-responders (93.8 + 3.3kg pre, 95 + 2.8kg post, p = 0.79). A significant fall in HbA1C was seen in DAS28 responders (60.5 + 6.3 pre vs 45.5 + 2.1 post, p = 0.012) but not non-responders (47.1+9.5 pre vs 39.4+13, p=0.144). A significant fall in SJC28 was seen in DAS28 responders (3.3 + 0.9 pre vs 1.2 + 0.6, p = 0.027) but not non-responders (4.2 + 2.8 pre vs 4.8 + 3.2, p = 0.66). Weight loss  following liraglutide was also significantly associated with achieving a DAS28 response by Chi Square analysis (p = 0.044). No significant differences were observed in baseline levels of DAS28, weight, HbA1C, SJC, ESR or CRP analysed according to subsequent DAS28 response grouping. 

Conclusion: In a cohort of patients with both inflammatory arthritis and T2DM, clinical efficacy of  the GLP-1 analogue liraglutide in reducing HbA1C and inducing weight loss was significantly associated with a concomitant reduction in inflammatory arthritis clinical disease activity by EULAR DAS28 response criteria. Further studies investigating common pathways of inflammation between these diseases may lead to novel therapeutic stretegies in the treatment of inflammatory arthritis.


Disclosure:

C. Sullivan,
None;

G. Gaoatswe,
None;

J. Gibney,
None;

M. L. Healy,
None;

M. Doran,
None;

D. Kane,
None;

D. O’Shea,
None;

R. Mullan,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-with-the-glucagon-like-peptide-1-analogue-liraglutide-is-associated-with-amelioration-of-disease-activity-in-a-prospective-cohort-study-of-patients-with-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology